Quantitative real-time RT-PCR analysis of PML-RARα mRNA in acute promyelocytic leukemia: Assessment of prognostic significance in adult patients from intergroup protocol 0129

Blood

Volumn 101, Issue 7, 2003, Pages 2521-2528

  Gallagher, Robert E ^a   Yeap, Beow Y ^b   Bi, Wanli ^b   Livak, Kenneth J ^b   Beaubier, Nike ^b   Rao, Sreenivas ^b   Bloomfield, Clara D ^b   Appelbaum, Frederick R ^b   Tallman, Martin S ^b   Slack, James L ^b   Willman, Cheryl L ^b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYBRID PROTEIN; MESSENGER RNA; RETINOIC ACID; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; TUMOR PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CELL; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CELL DENSITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; LEUKOCYTE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA ANALYSIS; TREATMENT OUTCOME; GENETICS; MIDDLE AGED; MORTALITY; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK; SURVIVAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; ODDS RATIO; ONCOGENE PROTEINS, FUSION; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0038446666     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-05-1357     Document Type: Article

References (35)

1. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021-1028.
2. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood. 1997;90:1014-1021.
3. Asou N, Adachi K, Tamura J, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. J Clin Oncol. 1998;6:78-85.
4. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood. 1999;94:1192-1200.
5. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood. 1999;93:4131-4143.
6. Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia. Blood. 1999;94:3015-3021.
7. Lo Coco F, Diverio D, Pandolfi P, et al. Molecular evaluation of residual disease as predictor of relapse in acute promyelocytic leukaemia. Lancet. 1992;340:1437-1438.
8. Miller Jr WH, Levine K, DeBlasio A, et al. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcriptase polymerase chain reaction assay for the PML/RAR-α fusion mRNA. Blood. 1993;82:1689-1694.
9. Huang W, Sun G-L, Li X-S, et al. Acute promyelocytic leukemia: clinical retevance relevance of two major PML-RARα isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood. 1993;82:1264-1269.
10. Diverio D, Pandolfi PP, Rossi V, et al. Monitoring of treatment outcome in acute promyelocytic leukemia by RT-PCR. Leukemia. 1994;8:1105-1107.
11. Diverio D, Rossi V, Avvisati G, et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARα fusion gene in patient with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. Blood. 1998;92:784-789.
12. Jurcic JG, Nimer SD, Scheinberg DA, et al. Prognostic significance of minimal residual disease detection and PML/RAR-α isoform type: long-term follow-up in acute promyelocytic leukemia. Blood. 2001;98:2651-2656.
13. Lo Coco F, Diverio D, Avvisati G, et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood. 1999;94:2225-2229.
14. Estey EH, Giles FJ, Beran M, et al. Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood. 2002;99:4222-4224.
15. Lanotte M, Martin-Thouvenin B, Najman S, et al. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood. 1991;77:1080-1086.
16. Kizaki M, Matsushita H, Takayama N, et al. Establishment and characterization of a novel acute promyelocytic leukemia cell line (UF-1) with retinoic acid-resistant features. Blood. 1996;88:1824-1833.
17. Slack JL, Bi WB, Livak KJ, et al. Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARα mRNA using real-time reverse-transcription-polymerase chain reaction. J Mol Diagn. 2001;3:141-149.
18. Tobal K, Lin-Yin JA. RT-PCR method with increased sensitivity shows persistence of PML-RARA fusion transcripts in patients in long-term remission ofAPL. Leukemia. 1998;12:1349-1354.
19. Gallagher RE, Willman CL, Slack JL, et al. Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood. 1997;90:1656-1663.
20. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-994.
21. Sykes PJ, Neoh SH, Briscoe MJ, et al. Quantitation of targets for PCR by use of limiting dilution. Biotechniques. 1992;13:444-449.
22. Ouspenskaia MV, Johnston DA, Roberts WM, Estrov Z, Zipf TF. Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and principles involved. Leukemia. 1995;9:321-328.
23. Cox D, Oakes D. The Analysis of Survival Data. London, United Kingdom: Chapman and Hall; 1984.
24. Lehmann E. Nonparametrics: Statistical Methods Based on Ranks. San Francisco, CA: Holden-Day; 1975.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
26. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2000;100:4298-4302.
27. Tallman M, Kwaan H. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood. 1992;79:543-553.
28. Di Bona E, Avvisati G, Castaman G, et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol. 2000;108:689-695.
29. De Botton S, Combret H, Sanz M, et al. Incidence, clinical features, and outcome of all-trans retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood. 1998;92:2712-2718.
30. Tallman MS, Andersen JW, Schiffer CA, et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood. 2000;95:90-95.
31. Radich JP, Gooley T, Bryant E, et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation, Blood. 2001;98:1701-1707.
32. Grimwade D, Howe K, Langabeer S, et al. Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RARα and RARα-PML assessment in patients who ultimately relapse. Leukemia. 1996;10:61-66.
33. Gallagher R, Ding W, Kim S, et al. Late-emerging PML-RARα mutant subclones in relapse acute promyelocytic leukemia (APL): a protocol INT0129 laboratory study [abstract]. Blood. 2001;98:718a.
34. Kanamaru A, Takemoto Y, Tanimoto M, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood. 1995;85:1202-1206.
35. Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247-1253.